May 9, 2018 / Clinical Trials

May 16 Webinar: Roche/Genentech Anti-Myostatin Adnectin RG6206 in Duchenne

Roche/Genentech will join Parent Project Muscular Dystrophy for a webinar on Wednesday, May 16 at 1:00 PM EDT to provide an update on their Anti-Myostatin Adnectin (RG6206) development program.

You will learn more about the team at Roche and its US affiliate, Genentech, and how they are collaborating with the Duchenne community. The team will also update you on their Anti-Myostatin Adnectin (RG6206) program, including the status of ongoing clinical studies.

For additional information regarding the RG6206 studies please visit (NCT03100630, NCT02515669, NCT03039686) or


  • Pat Furlong
    Founding President & CEO
    Parent Project Muscular Dystrophy


  • Sangeeta Jethwa
    Head, Patient Partnership, Rare Diseases, Basel, Switzerland
    Roche Switzerland
  • Michelle Krishnan
    Translational Medicine Leader, Basel, Switzerland
    Roche Switzerland
  • J.P. Sacksteder
    Alliance & Advocacy Relations, Government Affairs, San Francisco
  • Michael Solomonides
    Operations Program Leader, UK
    Roche UK

Please submit questions in advance to (subject line: Roche/Genentech Webinar) by Monday, May 14 at 12pm eastern.

Register Now >

Join Our Mailing List